Please login to the form below

Not currently logged in
Email:
Password:

Akinion appoints Dr Richard Jones as CEO

He joins the biotech firm from GlaxoSmithKline

Akinion Dr Richard JonesDr Richard Jones has been appointed as chief executive officer for privately-held Swedish biotech firm Akinion Pharmaceuticals.

He brings more than 20 years of pharmaceutical industry experience to the company and arrives from Novartis where he was vice president, medicines commercialisation leader, haematology, global oncology.

Before that Dr Jones served at GlaxoSmithKline, where he was most recently VP, global haematology medicines commercialisation leader.

In that role he was responsible for delivering the big pharma company's global haematology strategy, and prior to he served at Sanofi Genzyme as director and M&A transition lead for its transplant and oncology global business unit.

In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently in a phase I/II clinical trial.

27th January 2016

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...